Interaction Checker

Interaksi Ubrogepant

Ubrogepant (Ubrelvy) memiliki 80 interaksi terdokumentasi dalam label FDA dan lembar fakta yang kami indeks: 65 mayor, 8 moderat, 7 minor, dan 0 dengan label yang melaporkan tidak ada interaksi bermakna. Setiap entri di bawah ini mengutip kalimat yang mendasarinya. Halaman obat ini adalah titik awal, bukan putusan untuk situasi Anda.

Interaksi dari label

Interaksi mayor (65)

  • AmiodaronantiaritmiaMayor

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (label Ubrogepant, Kontraindikasi)

  • Aprepitantpenghambat CYP3A4Mayor

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (label Ubrogepant, Kontraindikasi)

  • Armodafinilstimulan SSPMayor

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (label Ubrogepant, Interaksi obat)

  • AtazanavirantiretroviralMayor

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (label Ubrogepant, Kontraindikasi)

  • Bosentanpenginduksi CYP3A4Mayor

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (label Ubrogepant, Interaksi obat)

  • DarunavirantiretroviralMayor

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (label Ubrogepant, Kontraindikasi)

  • Darunavir dan kobisistatantiretroviralMayor

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (label Ubrogepant, Kontraindikasi)

  • Deferasirokssuplemen zat besiMayor

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (label Ubrogepant, Interaksi obat)

  • DeksametasonkortikosteroidMayor

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (label Ubrogepant, Interaksi obat)

  • Diltiazempenghambat kanal kalsiumMayor

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (label Ubrogepant, Kontraindikasi)

  • DronedaronantiaritmiaMayor

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (label Ubrogepant, Kontraindikasi)

  • EfavirenzantiretroviralMayor

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (label Ubrogepant, Kontraindikasi)

  • Efavirenz, lamivudin, dan tenofovirantiretroviralMayor

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (label Ubrogepant, Kontraindikasi)

  • Elvitegravir, kobisistat, emtrisitabin, dan tenofovirantiretroviralMayor

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (label Ubrogepant, Kontraindikasi)

  • Eritromisinantibiotik makrolidaMayor

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (label Ubrogepant, Kontraindikasi)

  • EslikarbazepinantikonvulsanMayor

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (label Ubrogepant, Interaksi obat)

  • EtravirinantiretroviralMayor

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (label Ubrogepant, Interaksi obat)

  • EverolimusimunosupresanMayor

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (label Ubrogepant, Kontraindikasi)

  • FenitoinantikonvulsanMayor

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (label Ubrogepant, Interaksi obat)

  • FenobarbitalbarbituratMayor

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (label Ubrogepant, Interaksi obat)

  • Fentermin dan topiramatstimulan SSPMayor

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (label Ubrogepant, Interaksi obat)

  • Flukonazolantijamur azolMayor

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (label Ubrogepant, Kontraindikasi)

  • FosamprenavirantiretroviralMayor

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (label Ubrogepant, Kontraindikasi)

  • Fosaprepitantpenghambat CYP3A4Mayor

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (label Ubrogepant, Kontraindikasi)

  • FosfenitoinantikonvulsanMayor

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (label Ubrogepant, Interaksi obat)

  • GriseofulvinantijamurMayor

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (label Ubrogepant, Interaksi obat)

  • Imatinibpenghambat CYP3A4Mayor

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (label Ubrogepant, Kontraindikasi)

  • IsoniazidantibiotikMayor

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (label Ubrogepant, Kontraindikasi)

  • Itrakonazolantijamur azolMayor

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (label Ubrogepant, Kontraindikasi)

  • Ivakaftorpenghambat CYP3A4Mayor

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (label Ubrogepant, Kontraindikasi)

  • KarbamazepinantikonvulsanMayor

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (label Ubrogepant, Interaksi obat)

  • Ketokonazolantijamur azolMayor

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (label Ubrogepant, Kontraindikasi)

  • Klaritromisinantibiotik makrolidaMayor

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (label Ubrogepant, Kontraindikasi)

  • KlobazambenzodiazepinMayor

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (label Ubrogepant, Interaksi obat)

  • LenakapavirantiretroviralMayor

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (label Ubrogepant, Kontraindikasi)

  • Lopinavir dan ritonavirantiretroviralMayor

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (label Ubrogepant, Kontraindikasi)

  • Lorlatinibpenginduksi CYP3A4Mayor

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (label Ubrogepant, Interaksi obat)

  • Mifepristonpenghambat CYP3A4Mayor

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (label Ubrogepant, Kontraindikasi)

  • Mirabegronagonis beta-adrenergikMayor

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (label Ubrogepant, Kontraindikasi)

  • Mitapivatpenginduksi CYP3A4Mayor

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (label Ubrogepant, Interaksi obat)

  • Mitotanpenginduksi CYP3A4Mayor

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (label Ubrogepant, Interaksi obat)

  • Modafinilstimulan SSPMayor

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (label Ubrogepant, Interaksi obat)

  • Nafsilinantibiotik penisilinMayor

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (label Ubrogepant, Interaksi obat)

  • NefazodonantidepresanMayor

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (label Ubrogepant, Kontraindikasi)

  • NevirapinantiretroviralMayor

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (label Ubrogepant, Interaksi obat)

  • Nirmatrelvir dan ritonavirantivirusMayor

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (label Ubrogepant, Kontraindikasi)

  • OkskarbazepinantikonvulsanMayor

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (label Ubrogepant, Interaksi obat)

  • Palbosiklibpenghambat CYP3A4Mayor

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (label Ubrogepant, Kontraindikasi)

  • PerampanelantikonvulsanMayor

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (label Ubrogepant, Kontraindikasi)

  • Posakonazolantijamur azolMayor

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (label Ubrogepant, Kontraindikasi)

  • PrimidonantikonvulsanMayor

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (label Ubrogepant, Interaksi obat)

  • Ranolazinobat yang memperpanjang interval QTMayor

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (label Ubrogepant, Kontraindikasi)

  • RifabutinantibiotikMayor

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (label Ubrogepant, Interaksi obat)

  • RifampisinantibiotikMayor

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (label Ubrogepant, Interaksi obat)

  • RifapentinantibiotikMayor

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (label Ubrogepant, Interaksi obat)

  • RitonavirantiretroviralMayor

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (label Ubrogepant, Kontraindikasi)

  • SenobamatantikonvulsanMayor

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (label Ubrogepant, Kontraindikasi)

  • SiklosporinimunosupresanMayor

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (label Ubrogepant, Kontraindikasi)

  • Simetidinpenghambat H2Mayor

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (label Ubrogepant, Kontraindikasi)

  • Suvoreksantsedatif-hipnotikMayor

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (label Ubrogepant, Kontraindikasi)

  • Suzetriginpenginduksi CYP3A4Mayor

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (label Ubrogepant, Interaksi obat)

  • TikagrelorantiplateletMayor

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (label Ubrogepant, Kontraindikasi)

  • TopiramatantikonvulsanMayor

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (label Ubrogepant, Interaksi obat)

  • Verapamilpenghambat kanal kalsiumMayor

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (label Ubrogepant, Kontraindikasi)

  • Vorikonazolantijamur azolMayor

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (label Ubrogepant, Kontraindikasi)

Interaksi moderat (8)

  • Dekstrometorfan dan kuinidinobat serotonergikModerat

    Use of BCRP and/or P-gp only inhibitors (e.g., quinidine, carvedilol, eltrombopag, curcumin) may increase the exposure of ubrogepant [ s ee Clinical Pharmacology ( 12.3 ) ] . (label Ubrogepant, Interaksi obat)

  • Eltrombopagpenghambat OATP1B1Moderat

    Use of BCRP and/or P-gp only inhibitors (e.g., quinidine, carvedilol, eltrombopag, curcumin) may increase the exposure of ubrogepant [ s ee Clinical Pharmacology ( 12.3 ) ] . (label Ubrogepant, Interaksi obat)

  • FluvoksaminSSRIModerat

    Dose adjustment is recommended with concomitant use of UBRELVY and moderate CYP3A4 inhibitors (e.g., cyclosporine, ciprofloxacin, fluconazole, fluvoxamine, grapefruit juice) [see Dosage and Administration ( 2.2 )] . (label Ubrogepant, Interaksi obat)

  • GrapefruitMakanan dan minumanModerat

    Dose adjustment is recommended with concomitant use of UBRELVY and moderate CYP3A4 inhibitors (e.g., cyclosporine, ciprofloxacin, fluconazole, fluvoxamine, grapefruit juice) [see Dosage and Administration ( 2.2 )] . (label Ubrogepant, Interaksi obat)

  • Karvedilolpenyekat betaModerat

    Use of BCRP and/or P-gp only inhibitors (e.g., quinidine, carvedilol, eltrombopag, curcumin) may increase the exposure of ubrogepant [ s ee Clinical Pharmacology ( 12.3 ) ] . (label Ubrogepant, Interaksi obat)

  • KuinidinantiaritmiaModerat

    Use of BCRP and/or P-gp only inhibitors (e.g., quinidine, carvedilol, eltrombopag, curcumin) may increase the exposure of ubrogepant [ s ee Clinical Pharmacology ( 12.3 ) ] . (label Ubrogepant, Interaksi obat)

  • Kunyit (kurkumin)Herbal dan suplemenModerat

    Use of BCRP and/or P-gp only inhibitors (e.g., quinidine, carvedilol, eltrombopag, curcumin) may increase the exposure of ubrogepant [ s ee Clinical Pharmacology ( 12.3 ) ] . (label Ubrogepant, Interaksi obat)

  • SiprofloksasinfluorokuinolonModerat

    Dose adjustment is recommended with concomitant use of UBRELVY and moderate CYP3A4 inhibitors (e.g., cyclosporine, ciprofloxacin, fluconazole, fluvoxamine, grapefruit juice) [see Dosage and Administration ( 2.2 )] . (label Ubrogepant, Interaksi obat)

Penyebutan minor (7)

  • Butalbital dan parasetamolbarbituratMinor

    In patients taking strong CYP3A4 inducers (e.g., phenytoin, barbiturates, rifampin, St. (label Ubrogepant, Interaksi obat)

  • Butalbital, aspirin, dan kafeinbarbituratMinor

    In patients taking strong CYP3A4 inducers (e.g., phenytoin, barbiturates, rifampin, St. (label Ubrogepant, Interaksi obat)

  • Butalbital, aspirin, kafein, dan kodeinbarbituratMinor

    In patients taking strong CYP3A4 inducers (e.g., phenytoin, barbiturates, rifampin, St. (label Ubrogepant, Interaksi obat)

  • Butalbital, parasetamol, dan kafeinbarbituratMinor

    In patients taking strong CYP3A4 inducers (e.g., phenytoin, barbiturates, rifampin, St. (label Ubrogepant, Interaksi obat)

  • Butalbital, parasetamol, kafein, dan kodeinbarbituratMinor

    In patients taking strong CYP3A4 inducers (e.g., phenytoin, barbiturates, rifampin, St. (label Ubrogepant, Interaksi obat)

  • Fenobarbital, hiosiamin, atropin, dan skopolaminbarbituratMinor

    In patients taking strong CYP3A4 inducers (e.g., phenytoin, barbiturates, rifampin, St. (label Ubrogepant, Interaksi obat)

  • MetoheksitalbarbituratMinor

    In patients taking strong CYP3A4 inducers (e.g., phenytoin, barbiturates, rifampin, St. (label Ubrogepant, Interaksi obat)

Periksa Ubrogepant terhadap semua yang Anda gunakan. Tambahkan seluruh daftar Anda; setiap pasangan diperiksa sekaligus.

Buka di pemeriksa

Bukan nasihat medis. Tingkat keparahan mencerminkan kata-kata dalam label, bukan keadaan Anda. Tanda “mayor” bisa merupakan hal yang rutin di bawah pengawasan, dan tanda “minor” bisa menjadi penting pada dosis tinggi. Tanyakan kepada apoteker.